Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 8/20 | 0.50 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14243737 | 1.00 | NAAA (0.50) | NAAAFAAHALDH1A1EPHX2PPARA | |
| SCHEMBL17756150 | 1.00 | NAAA (0.50) | NAAAFAAHALDH1A1EPHX2PPARA | |
| SCHEMBL6599302 | 0.97 | NAAA (0.52) | NAAAFAAHALDH1A1EPHX2PPARA | |
| SCHEMBL14243651 | 0.97 | NAAA (0.52) | NAAAFAAHALDH1A1EPHX2PPARA | |
| SCHEMBL14243652 | 0.97 | NAAA (0.52) | NAAAFAAHALDH1A1EPHX2PPARA | |
| SCHEMBL8828113 | 0.96 | NAAA (0.54) | NAAAFAAHALDH1A1EPHX2PPARA | |
| SCHEMBL4299854 | 0.93 | NAAA (0.46) | NAAAFAAHALDH1A1PPARAIDH1 | |
| SCHEMBL4299858 | 0.93 | NAAA (0.46) | NAAAFAAHALDH1A1PPARAIDH1 | |
| SCHEMBL19713409 | 0.93 | NAAA (0.46) | NAAAFAAHALDH1A1PPARAIDH1 | |
| SCHEMBL17762203 | 0.89 | NAAA (0.51) | NAAAFAAHALDH1A1PPARAIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111440046-B | Synthetic method of sex pheromone (S) -14-methyl-1-octadecene of lepidoptera pest phyllocladia persica | 塔里木大学 | 2022-09-16 | — | — | CN | claimed |
| CN-111440046-A | Synthesis method of sex pheromone (S) -14-methyl-1-octadecene of lepidoptera pest peach leaf miner | 塔里木大学 | 2020-07-24 | — | — | CN | claimed |
| CN-111440046-B | Synthetic method of sex pheromone (S) -14-methyl-1-octadecene of lepidoptera pest phyllocladia persica | 塔里木大学 | 2022-09-16 | — | — | CN | disclosed |
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | UNIVERSITY OF HAWAII (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3437640-B1 | AGENT FOR TREATING SYNUCLEINOPATHY | UNIV TOHOKU (JP) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020251953-A1 | STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-17 | — | — | WO | disclosed |
| CN-111440046-A | Synthesis method of sex pheromone (S) -14-methyl-1-octadecene of lepidoptera pest peach leaf miner | 塔里木大学 | 2020-07-24 | — | — | CN | disclosed |
| US-10709688-B2 | Agent for treating synucleinopathy | TOHOKU UNIVERSITY (JP) | 2020-07-14 | — | — | US | disclosed |
| US-10709688-B2 | Agent for treating synucleinopathy | TOHOKU UNIVERSITY (JP) | 2020-07-14 | — | — | US | disclosed |
| CN-111356456-A | 2-arylsulfonamido-iV-arylacetamide derived Stat3 inhibitor | 夏威夷大学 | 2020-06-30 | — | — | CN | disclosed |
| US-20190125726-A1 | AGENT FOR TREATING SYNUCLEINOPATHY | TOHOKU UNIVERSITY (JP) | 2019-05-02 | — | — | US | disclosed |
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| WO-2007056143-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056143-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | STAT3, JAK2, STAT5A | NAAA 2957/4885FAAH 4793/4885ALDH1A1 1312/4885 |
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | NAAA 3559/4885FAAH 4312/4885ALDH1A1 2159/4885 |
| US-10709688-B2 | Agent for treating synucleinopathy | SNCA, PARK7, SYNJ1 | NAAA 2707/4885FAAH 1647/4885ALDH1A1 2189/4885 |
| US-20190125726-A1 | AGENT FOR TREATING SYNUCLEINOPATHY | SNCA, PARK7, SYNJ1 | NAAA 2707/4885FAAH 1647/4885ALDH1A1 2189/4885 |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | NAAA 3559/4885FAAH 4312/4885ALDH1A1 2159/4885 |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | NAAA 3559/4885FAAH 4312/4885ALDH1A1 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.